GPBAR1 and fatty liver disease: The dual receptor agonist INT-767, which synergistically activates the FXR/TGR5 signaling pathway, demonstrates a multifaceted ameliorative effect on hepatic steatosis, inflammatory damage, and fibrosis progression in animal models, offering novel insights for the combined treatment of MASH [146].